Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 14, 2019

SELL
$16.91 - $36.27 $251,350 - $539,117
-14,864 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$31.0 - $36.3 $96,286 - $112,747
-3,106 Reduced 17.28%
14,864 $529,000
Q1 2019

May 14, 2019

BUY
$31.58 - $46.35 $77,149 - $113,233
2,443 Added 15.73%
17,970 $604,000
Q4 2018

Feb 14, 2019

BUY
$30.43 - $56.65 $219,948 - $409,466
7,228 Added 87.09%
15,527 $511,000
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $385,571 - $568,398
8,299 New
8,299 $505,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $191M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Srb Corp Portfolio

Follow Srb Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srb Corp, based on Form 13F filings with the SEC.

News

Stay updated on Srb Corp with notifications on news.